Blood-based biomarkers of tumor sensitivity to PD-1 antagonists

US11326211B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Mark Ayers · Pennington, US
• Jared Lunceford · Washington, US
• Andrey Loboda · Canton, US
• Michael Nebozhyn · Yeadon, US
• Terrill K. McClanahan · Sunnyvale, US
• Heather Hirsch · Brookline, US

Key dates

• Filing date: Apr 12, 2016
• Grant date: May 10, 2022
• Expiry date: Jan 20, 2038

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/52
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

The present disclosure describes baseline and on treatment blood-based gene signature biomarkers that are predictive of tumor sensitivity to therapy with a PD-1 antagonist. The on-treatment biomarkers comprise a PD-L1 gene signature or an interferon gamma gene signature and the baseline gene signature biomarker comprises genes associated with the oxidative phosphorylation pathway. The disclosure also provides methods and kits for testing tumor samples for these biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results.